LB Pharmaceuticals appoints Susan G. Kozauer as chief medical officer
Kozauer brings extensive neuropsychiatric drug development experience to lead clinical trials for LB-102 and its Phase 3 NOVA-2 trial.
Latest LB Pharmaceuticals News & Updates
See the latest news and media coverage for LB Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing neuropsychiatric therapies
lbpharma.us- Founded year
- 2015
- Company type
- Private company
- Number of employees
- 10–60
- Industry
- Pharmaceuticals
Last updated
Latest news about LB Pharmaceuticals
In short: LB Pharmaceuticals accelerated Phase 3 schizophrenia data timelines and secured $150 million to extend its cash runway into 2029.
Company announcements
LB Pharmaceuticals appoints Joseph Miller as chief financial officer
The executive brings over two decades of biopharmaceutical finance experience to guide the company through upcoming clinical trial results and potential product commercialization.
LB Pharmaceuticals announces $150 million private placement
The funding will support pipeline expansion of LB-102 into new indications and for working capital.
LB Pharmaceuticals accelerates timeline for Phase 3 trial results
The company now expects to report topline data in first half of 2027, ahead of prior guidance.
Media coverage
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatry.
LB Pharmaceuticals Inc.: Q2 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — LB Pharmaceuticals Inc. (LBRX) on Tuesday reported a loss of $51.6 million in its second quarter. The...
LB Pharmaceuticals Accelerates LB-102 Schizophrenia Program; Phase 3 Data...
LB Pharmaceuticals (LBRX) reported Q2 2026 results and highlighted progress for LB-102, with Phase 3 NOVA-2 schizophrenia topline data now expected in 1H 2027. The...
LB Pharmaceuticals Advances LB-102 with $150M Funding; Shares Ne
On August 11, 2026, LB Pharmaceuticals announced a $150 million private placement to accelerate...
Never miss news about LB Pharmaceuticals
Track LB Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
LB Pharmaceuticals competitors & trending companies
Browse news for competitors to LB Pharmaceuticals and other trending companies.
Teva
Sensorium
AtaiBeckley
Oculis
Ticketplus
HELP Therapeutics
CMC
ManpowerGroup
Arcosa
Alliance Entertainment
QXO
Reliant Stones
Amber
The Pool Tile Co
Cinajus
Armstone
Eco Outdoor
Sareen Stone
Stone Planet
Salience Labs
Trio Petroleum
Arianespace
American Eagle
AEO
OLB
Compass
MAQS
Roschier
Möller & Partners
Normain
Incentive Industrier
Pinecone
SSHL
Videobuddy